Interferon beta-1a

Faron’s Financial Statement Release January 1 to December 31, 2023

Retrieved on: 
星期三, 三月 13, 2024
Head, Q&A, Survival, Immunotherapy, Patient, Medicine, Standard of care, CMML, Macrophage, Faron Pharmaceuticals, Neoplasm, EET, Rheumatology, PD-1, TME, PR, ASH, AML, Cancer, Johnson & Johnson, Safety, Azacitidine, MDS, BLA, Decitabine, Food, ODD, Nasdaq First North, PD, Tumor microenvironment, Manuscript, CRS, SICAV, MD, Interferon beta-1a, Haematopoietic system, GMT, FDA, AIM, Neurotoxicity, Infection, EUR, Sanofi, SOC, Metabolism, European Hematology Association, EDT, MBA, IPF, Facility, Treasury, Society, Cytokine release syndrome, CPA, Pharmaceutical industry

As at March 13, 2024, the Company is in compliance with all IPF financial covenants as agreed with the waiver letter.

Key Points: 
  • As at March 13, 2024, the Company is in compliance with all IPF financial covenants as agreed with the waiver letter.
  • Loss for the period for the financial year ended December 31, 2023, was EUR 30,9 million (2022: EUR 28,7 million).
  • In June 2023, Faron conducted a placement of 2,601,510 newly issued treasury shares to investors to raise EUR 6,6 million gross.
  • In October 2023, the Company successfully raised EUR 7,1 million gross through the issuance of 2,491,998 ordinary shares to investors.

Cadenza Bio, Inc. Appoints Michael A. Panzara, MD, MPH, to its Board of Directors

Retrieved on: 
星期四, 四月 4, 2024
Neurology, Sanofi, Alemtuzumab, Myelin, Public health, Growth, Massachusetts General Hospital, Multiple sclerosis, University, Patient, Research, Inflammation, Biology, Interferon beta-1a, MPH, Brigham and Women's Hospital, DSM-IV codes, Hospital, Drug development, Natalizumab, Rheumatology, Pharmaceutical industry

He also serves on the board of directors of Athira Pharma, Inc., a neurology-focused clinical-stage biopharmaceutical company.

Key Points: 
  • He also serves on the board of directors of Athira Pharma, Inc., a neurology-focused clinical-stage biopharmaceutical company.
  • "We are delighted to welcome Dr. Panzara to our board of directors," said Dr. Carol Curtis, chief executive officer of Cadenza Bio.
  • "His extensive experience in developing therapies for MS and other neurological disorders aligns perfectly with our mission at Cadenza Bio.
  • "I look forward to joining the board of directors at Cadenza Bio at such an exciting time in the growth of the company," said Dr. Panzara.

Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Retrieved on: 
星期六, 一月 6, 2024
Urinary tract infection, Patient, Medical Subject Headings, Marketing, Agency, Jaw, INN, Interferon beta-1a, Immune system, Fever, Tears, ATC, Disability, Multiple sclerosis, Kidney, Hypertension, International, Blood, RRMS, Attack, Spinal cord, Disease, Headache, Language, Brain, Myocardial infarction, Eye, Heart, Inflammation, Thyroid, Stroke, Head, Angina, European Medicines Agency, Infection, Coagulopathy, Lymphocyte, HIV, Select, Central nervous system, Human, Safety, Anatomy, Checklist, Sclerosis, IIA, Optic nerve, Neck, Rash, CD52, Medical device

Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

EF Hutton Appoints David Sans as Head of Healthcare

Retrieved on: 
星期三, 一月 3, 2024
EF Hutton, Pfizer, Corporate law, Biotechnology, Business, Chemical engineering, Fellow, Doctor of Philosophy, ImClone Systems, Novartis, American Academy, Regenerative medicine, ETH, Corporate development, Head, Agilent Technologies, Therapy, Labcorp, Interferon beta-1a, Pharmaceutical industry

NEW YORK, NY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- EF Hutton, an investment bank headquartered in New York, today announced the appointment of David Sans, PhD, FAARM MBA, as Managing Director, Head of Healthcare, to lead the Company’s Healthcare & Life Sciences Investment Banking Team.

Key Points: 
  • NEW YORK, NY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- EF Hutton, an investment bank headquartered in New York, today announced the appointment of David Sans, PhD, FAARM MBA, as Managing Director, Head of Healthcare, to lead the Company’s Healthcare & Life Sciences Investment Banking Team.
  • David Sans, PhD, FAARM MBA, brings many years of biotech and pharma experience in corporate finance, business development, operational, and commercial roles spanning both large pharmaceutical and emerging biotechnology companies.
  • “We continue to see innovation and opportunity across the healthcare continuum in biotechnology, medical devices, healthcare IT, healthcare services, and therapeutics, and are privileged to have someone of David’s caliber serve as Head of Healthcare,” said Joseph T. Rallo, Chief Executive Officer of EF Hutton.
  • He will oversee all healthcare transactions at EF Hutton, spearheading and driving a wide range of industry transactions.

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Urine, Medical Subject Headings, Diarrhea, Marketing, INN, Risk, Immune system, Stomach, Interferon beta-1a, ATC, Pain, Multiple sclerosis, Capsule, International, RRMS, Spinal cord, Disease, PML, Ageing, Nausea, Language, Brain, Mouth, Eye, Inflammation, Flushing, European Medicines Agency, Food, Gene, Glatiramer acetate, Select, Central nervous system, Patient, Safety, Encephalitis, Anatomy, Sclerosis, Optic nerve, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 42, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Patient, Medical Subject Headings, Marketing, MRI, INN, Risk, Interferon beta-1a, Immune system, Fatigue, Infection, Registry, ATC, Antibody, Gadolinium, Disability, Multiple sclerosis, International, Attack, Spinal cord, Disease, Common, PML, Nose, Headache, Nausea, Brain, Language, Urinary tract infection, Inflammation, Cancer, Nerve, Dizziness, Skin cancer, Allergy, DMT, Death, European Medicines Agency, Nervous system, Select, Carcinoma, Safety, Encephalitis, Anatomy, Arthralgia, Sclerosis, IIA, Magnetic resonance imaging, Medical device

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 42, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 42, Status: Authorised

Titan Partners Group Announces Addition of Dr. David Sans as Head of Healthcare

Retrieved on: 
星期一, 三月 27, 2023
Titan, Drug development, Avista Capital Partners, Doctor of Philosophy, ETH, Cetuximab, National Comprehensive Cancer Network, Wall Street, Head, American Academy, MBA, Acute leukemia, Multiple sclerosis, Partners Group, Eli Lilly, Regenerative medicine, Novartis, Chemical engineering, FINRA, Interferon beta-1a, University Ramon Llull, BMS, Medtech, ImClone Systems, Pfizer, Pharmaceutical industry, Imatinib

NEW YORK, March 27, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Titan Partners Group LLC, a division of American Capital Partners, LLC (“Titan Partners”), announces today that Dr. David Sans has joined the firm as head of healthcare.

Key Points: 
  • NEW YORK, March 27, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Titan Partners Group LLC, a division of American Capital Partners, LLC (“Titan Partners”), announces today that Dr. David Sans has joined the firm as head of healthcare.
  • Dr. Sans will lead the healthcare team, which covers companies in the biopharmaceuticals, diagnostics, medtech and specialty pharmaceuticals sectors.
  • “We are excited to bring in David Sans to join Titan Partners and lead our healthcare practice as we continue to expand our footprint and capacity in this sector,” commented Michael Sands, Titan Partners co-founder and partner.
  • Titan Partners is committed to building out a leading healthcare division.

Dunad Therapeutics Appoints Michael Bonney as Chair of Board of Directors

Retrieved on: 
星期一, 一月 9, 2023
Biotechnology, General Health, Health, Science, Research, Multiple sclerosis, Merck, Therapy, Marketing, Biogen, Sarepta Therapeutics, Interferon beta-1a, Cubist Pharmaceuticals, Bristol Myers Squibb, Chairperson, Pharmaceutical industry, Alnylam Pharmaceuticals

Dunad Therapeutics, a biopharmaceutical company developing covalent small molecule therapies with a focus on protein degradation, today announced the appointment of Michael Bonney as Chair of its Board of Directors.

Key Points: 
  • Dunad Therapeutics, a biopharmaceutical company developing covalent small molecule therapies with a focus on protein degradation, today announced the appointment of Michael Bonney as Chair of its Board of Directors.
  • Mr. Bonney brings more than 30 years of life sciences industry leadership experience, including serving as President and Chief Executive Officer of Cubist Pharmaceuticals and Executive Chair of Alnylam Pharmaceuticals.
  • More recently, Mr. Bonney held the position of Chief Executive Officer and Chair of Kaleido Biosciences, a company focused on developing microbiome therapies.
  • In addition to Alnylam, Mr. Bonney has served as Board Chair of Magenta Therapeutics and Director of several biopharma companies including Sarepta Therapeutics, Bristol Myers Squibb, Celgene and Syros Pharmaceuticals.

Qunol Taps Legendary Skateboarder and Entrepreneur Tony Hawk as Brand Ambassador

Retrieved on: 
星期三, 一月 4, 2023
Partnership, Club, Walmart, Coenzyme Q10, Magnesium, BJS, Food, Water, Skating, Inflammation, Multimedia, US1, Rite Aid, Disease, Absorption, Nutrient, Capsule, CVS, Health, Heart, Interferon beta-1a, Sam's Club, Life, Human, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dietary supplement, Walgreens, Costco, Amazon

NEW YORK, Jan. 4, 2023 /PRNewswire/ -- Qunol, a wellness brand offering a rich selection of nutritional supplements, announces their partnership with legendary skateboarder and entrepreneur Tony Hawk as the brand's newest ambassador starting January 1, 2023. Hawk was originally introduced to the brand when his doctor suggested taking CoQ10 to pair with his statin medication. Hawk tried other CoQ10 brands but settled on Qunol with its Ultra CoQ10 that offers 3x better absorption than regular2 CoQ10. "I take a statin every day to manage my high cholesterol, but statins can deplete my CoQ10 levels, so my doctor recommended taking a CoQ10 supplement. I choose Qunol because it has the #1 cardiologist recommended form3 of CoQ104," says Hawk

Key Points: 
  • NEW YORK, Jan. 4, 2023 /PRNewswire/ -- Qunol, a wellness brand offering a rich selection of nutritional supplements, announces their partnership with legendary skateboarder and entrepreneur Tony Hawk as the brand's newest ambassador starting January 1, 2023.
  • Hawk was originally introduced to the brand when his doctor suggested taking CoQ10 to pair with his statin medication.
  • Hawk tried other CoQ10 brands but settled on Qunol with its Ultra CoQ10 that offers 3x better absorption than regular2 CoQ10.
  • Qunol is the #1 selling brand of both Turmeric and CoQ10 supplements in the US1.

Super Carrier and Smart Aviation Achievements aired in the 2022 North Bund International Aviation Forum

Retrieved on: 
星期四, 十一月 24, 2022
IATA, Human, China Eastern Airlines, Shanghai Airport Authority, Digital economy, Aviation, COVID-19, Airline, ACI, Interferon beta-1a

About 150 guests from domestic and foreign civil aviation enterprises, industry associations, and colleges attended the forum online or in person.

Key Points: 
  • About 150 guests from domestic and foreign civil aviation enterprises, industry associations, and colleges attended the forum online or in person.
  • They shared their insights around topics such as digital transformation, green aviation, and smart aviation via speeches and roundtable discussion.
  • The North Bund International Aviation Forum fully reflects the openness, innovation and inclusiveness of Shanghai.
  • Major achievements including "Super Carrier + Smart Aviation" of CEAH and "Digital Construction Achievements" of Avinex were released at the forum.